This brand name is authorized in Estonia, Malta
The drug REMEVIA contains one active pharmaceutical ingredient (API):
|
1
Sitagliptin
UNII QFP0P1DV7Z - SITAGLIPTIN
|
|
Sitagliptin is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors. The improvement in glycaemic control observed with this medicinal product may be mediated by enhancing the levels of active incretin hormones. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10BH01 | Sitagliptin | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1853872, 1853883, 1853894, 1853906, 1853917, 1853928, 1853939, 1853940, 1853951, 1853962, 1853973, 1853984, 1853995, 1854008 |
| Country: MT | Medicines Authority | Identifier(s): MA084/11601, MA084/11602, MA084/11603 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
